The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.82

Today's change0.00 0.00%
Updated February 26 4:01 PM EST. Delayed by at least 15 minutes.
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.82

Today's change0.00 0.00%
Updated February 26 4:01 PM EST. Delayed by at least 15 minutes.

Boston Scientific Corp closed at (U.S.)$16.82.

Over the last five days, shares have gained 2.25% and 26.94% year to date. Shares have outperformed the S&P 500 by 11.69% during the last year.

Key company metrics

  • Open(U.S.) $16.84
  • Previous close(U.S.) $16.82
  • High(U.S.) $16.88
  • Low(U.S.) $16.64
  • Bid / Ask-- / --
  • YTD % change+26.94%
  • Volume11,324,182
  • Average volume (10-day)19,236,747
  • Average volume (1-month)15,212,906
  • Average volume (3-month)13,043,983
  • 52-week range(U.S.) $11.10 to (U.S.) $16.97
  • Beta1.04
  • Trailing P/E84.39×
  • P/E 1 year forward18.57×
  • Forward PEG1.85×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.20
Updated February 26 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+3.62%

Based on its net profit margin of 3.62%, Boston Scientific Corp is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue1,8871,8461,8731,774
Total other revenue--------
Total revenue1,8871,8461,8731,774
Gross profit1,3281,3051,3141,239
Total cost of revenue559541559535
Total operating expense1,7801,7821,9421,577
Selling / general / administrative753735737660
Research & development208212206191
Depreciation / amortization111109109109
Interest expense (income), net operating--------
Unusual expense (income)12416430642
Other operating expenses, total25212540
Operating income10764-69197
Interest income (expense), net non-operating-54-54-53-54
Gain (loss) on sale of assets--------
Other--------
Income before tax463-104146
Income after tax87434133
Income tax, total-41-40-10813
Net income87434133
Total adjustments to net income--------
Net income before extra. items87434133
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items87434133
Inc. avail. to common incl. extra. items87434133
Diluted net income87434135
Dilution adjustment------2
Diluted weighted average shares1,3501,3481,3451,349
Diluted EPS excluding extraordinary itemsvalue per share0.060.030.000.10
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.120.110.150.12